Fineline Cube

Follow:
14486 Articles
Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic
CompanyDeals

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic

Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials
CompanyDrug

Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First
Company

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First

BeOne's Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
CompanyDrug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Biokin's iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First
CompanyDrug

Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy
CompanyDeals

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients
CompanyDrug

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients
CompanyDrug

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915
CompanyDeals

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915

Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint
CompanyDrug

Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint

Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus
CompanyDeals

Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus

Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China
CompanyDrug

Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China